Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 875 of 1475 entries
View as:

A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00002261 Org: User:
Start: - End: - Due: -

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01629732 Org: User:
Start: 03/31/13 End: 06/30/14 Due: 06/30/15

Expanded Access for Anti-IL8

Phase: N/A Priority: Normal
NCT ID: NCT05210894 Org: User:
Start: - End: - Due: -

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03197779 Org: User:
Start: 11/18/13 End: 01/24/17 Due: 01/24/18

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT05136677 Org: User:
Start: 01/25/22 End: 10/08/26 Due: 10/08/27

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Phase: N/A Priority: Normal
NCT ID: NCT01309932 Org: User:
Start: 03/31/11 End: 09/30/14 Due: 09/30/15

A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT06581055 Org: User:
Start: 11/30/24 End: 03/30/25 Due: 03/30/26

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05298592 Org: User:
Start: 03/31/22 End: 08/16/24 Due: 08/16/25

A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke

Phase: N/A Priority: Normal
NCT ID: NCT04126486 Org: User:
Start: 12/17/19 End: 06/30/23 Due: 06/30/24

Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00094991 Org: User:
Start: 05/31/04 End: 05/31/06 Due: 05/31/07

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT05952089 Org: User:
Start: 08/17/23 End: 03/19/24 Due: 03/19/25

Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00855764 Org: User:
Start: 10/31/05 End: 10/31/06 Due: 10/31/07

A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02341625 Org: User:
Start: 06/19/15 End: 05/07/20 Due: 05/07/21

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00371683 Org: User:
Start: 11/30/06 End: 05/31/08 Due: 05/31/09

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05303220 Org: User:
Start: 04/08/22 End: 08/18/22 Due: 08/18/23

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Phase: N/A Priority: Normal
NCT ID: NCT03165409 Org: User:
Start: 02/27/17 End: 09/30/17 Due: 09/30/18

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02186249 Org: User:
Start: - End: - Due: -

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02079480 Org: User:
Start: 05/31/14 End: 04/30/16 Due: 04/30/17

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT01973049 Org: User:
Start: 12/31/13 End: 11/30/14 Due: 11/30/15

An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Phase: N/A Priority: Normal
NCT ID: NCT00677313 Org: User:
Start: 03/31/09 End: 01/31/15 Due: 01/31/16

Study of Relatlimab in Combination With Nivolumab in Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT05498480 Org: User:
Start: 07/27/22 End: 01/18/24 Due: 01/18/25

Study of BMS-663513 in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00309023 Org: User:
Start: 12/31/05 End: 09/30/09 Due: 09/30/10

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Phase: N/A Priority: Normal
NCT ID: NCT01309945 Org: User:
Start: 04/30/11 End: 01/31/13 Due: 01/31/14

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

Phase: N/A Priority: Normal
NCT ID: NCT04311710 Org: User:
Start: 06/25/20 End: 01/18/23 Due: 01/18/24

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Phase: N/A Priority: Normal
NCT ID: NCT03459222 Org: User:
Start: 05/30/18 End: 02/19/25 Due: 02/19/26